City Therapeutics, Inc. Common Stock Stock Price Today

$18.10 USD
▼ -4.64% today

City Therapeutics, Inc. Common Stock stock price today. City Therapeutics, Inc. Common Stock (NASDAQ:CTY) is currently trading at $18.10 USD, down 4.64% today. Over the past 52 weeks, shares have ranged between $16.41 and $22.14. This page tracks City Therapeutics, Inc. Common Stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see City Therapeutics, Inc. Common Stock market capitalisation.

Share Price of City Therapeutics, Inc. Common Stock — Daily History & Trading Volume

Share price of City Therapeutics, Inc. Common Stock over the past year. The chart below tracks City Therapeutics, Inc. Common Stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.

City Therapeutics, Inc. Common Stock Stock Trading Volume

City Therapeutics, Inc. Common Stock stock trading volume shows how many shares changed hands each day on the NASDAQ exchange.

City Therapeutics, Inc. Common Stock Income Statement — Revenue, Profit & Earnings by Year

City Therapeutics, Inc. Common Stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024201920182017
Total Revenue $13.56 Million $2.78 Million $8.16 Billion $8.49 Billion $8.55 Billion
Cost of Revenue — — $2.44 Billion $2.77 Billion $2.88 Billion
Gross Profit — — $5.72 Billion $5.73 Billion $5.67 Billion
Research & Development $58.42 Million $25.68 Million — — —
SG&A $15.06 Million $6.19 Million $659.00 Million $799.00 Million $925.00 Million
Total Operating Expenses $73.48 Million $31.87 Million $659.00 Million $5.83 Billion $6.24 Billion
Operating Income $-59.92 Million $-29.09 Million $2.88 Billion $2.66 Billion $2.31 Billion
EBITDA $-55.08 Million $-26.96 Million $3.83 Billion $4.04 Billion $3.84 Billion
EBIT $-56.25 Million $-27.39 Million $2.47 Billion $2.61 Billion $2.26 Billion
Interest Expense $2.26 Million $448.00K — $448.00 Million $465.00 Million
Income Before Tax $-58.51 Million $-27.84 Million $2.47 Billion $2.16 Billion $1.79 Billion
Income Tax Expense — — $641.00 Million $494.00 Million $134.00 Million
Net Income $-58.51 Million $-27.84 Million $1.83 Billion $1.67 Billion $1.66 Billion

City Therapeutics, Inc. Common Stock Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes City Therapeutics, Inc. Common Stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024201920182017
Total Assets $149.77 Million $145.35 Million $21.00 Billion $20.58 Billion $20.87 Billion
Total Current Assets $116.87 Million $128.90 Million $2.49 Billion $1.85 Billion $1.77 Billion
Cash & Equivalents — — — — —
Short-term Investments — — — — —
Net Receivables $1.21 Million $1.35 Million $514.00 Million $546.00 Million $646.00 Million
Inventory — — — — —
Property, Plant & Equipment — — — — —
Goodwill — — $9.36 Billion $9.36 Billion $9.36 Billion
Total Liabilities $234.42 Million $174.78 Million $10.88 Billion $10.71 Billion $11.53 Billion
Total Current Liabilities $38.04 Million $20.74 Million $3.41 Billion $2.27 Billion $2.20 Billion
Long-term Debt $31.06 Million — — — —
Net Debt — — $5.95 Billion $5.95 Billion $7.28 Billion
Total Stockholder Equity $-84.66 Million $-29.43 Million $10.12 Billion $9.87 Billion $9.34 Billion
Retained Earnings $-89.10 Million $-30.60 Million $67.00 Million $-182.00 Million $-713.00 Million

City Therapeutics, Inc. Common Stock Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how City Therapeutics, Inc. Common Stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024201920182017
Operating Cash Flow $-41.61 Million $-20.39 Million $3.33 Billion $3.79 Billion $2.44 Billion
Capital Expenditures $2.40 Million $3.54 Million $1.05 Billion $1.04 Billion $1.33 Billion
Free Cash Flow $-44.02 Million $-23.93 Million $2.28 Billion $2.75 Billion $1.11 Billion
Investing Cash Flow — — $-1.72 Billion $-1.15 Billion $-1.44 Billion
Financing Cash Flow $30.86 Million $149.44 Million $-1.61 Billion $-2.63 Billion $-1.00 Billion
Dividends Paid — — $1.60 Billion $1.27 Billion $1.00 Billion
Stock-Based Compensation $3.00 Million $1.00 Million $26.00 Million $24.00 Million $27.00 Million
Depreciation $1.17 Million $424.00K $1.36 Billion $1.44 Billion $1.58 Billion
Change in Cash $-13.13 Million $125.67 Million $-5.00 Million $2.00 Million $-4.00 Million

City Therapeutics, Inc. Common Stock Earnings History — EPS Actual vs. Analyst Estimates

Track City Therapeutics, Inc. Common Stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Earnings history is not currently available for City Therapeutics, Inc. Common Stock.